Medicinal Chemistry
Drug Design & Synthesis
Na Ye
Associate Professor
B.S. Shenyang Pharmaceutical University, 2008
Ph.D. Shanghai Institute of Materia Medica, 2013
Postdoctoral Fellow, University of Texas Medical Branch, 2013-2016

Research interests
1. Development of novel therapeutics targeting central nervous system diseases
2. Design and synthesis of small molecules as anti-cancer drugs


Representative publications
1)    Yuan, B.; Ye, N.;# Song, S. S.; Wang, Y. T.; Song, Z.; Chen, H. D.; Chen, C. H.; Huan, X. J.; Wang, Y. Q.; Su, Y.; Shen, Y. Y.; Sun, Y. M.; Yang, X. Y.; Chen, Y.; Guo, S. Y.; Gan, Y.; Gao, Z. W.; Chen, X. Y.; Ding, J.; He, J. X.; Zhang, A.; Miao, Z. H. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials. Cancer lett., 2017, 386, 47-56. (# co-first author)

2)    Ye, N.; Zhu, Y.; Liu, Z.; Mei, F. C.; Chen, H.; Wang, P.; Cheng, X.; Zhou, J. Identification of novel 2-(benzo[d]isoxazol-3-yl)-2-oxo-N-phenylacetohydrazonoyl cyanide analoguesas potent EPAC antagonists. Eur. J. Med. Chem. 2017, 134, 62-71.

3)    Ye, N.; Shi, P.-Y.; Zhou, J. Therapetic Potential of Spirooxindoles as Antiviral Agents. ACS Infect. Dis., 2016, 2, 382-292.

4)    Ye, N.; Zhu, Y.; Chen, H.; Liu, Z.; Mei, F. C.; Wild, C.; Chen, H.; Cheng, X.; Zhou, J. Structure–Activity Relationship Studies of Substituted 2-(Isoxazol-3-yl)-2-oxo-N’-phenyl-acetohydrazonoyl Cyanide Analogues: Identification of Potent Exchange Proteins Directly Activated by cAMP (EPAC) Antagonists. J. Med. Chem., 2015, 58, 6033-6047.

5)    Ye, N.; Ding, Y.; Wild, C.; Shen, Q.; Zhou, J. Small molecule inhibitors targeting activator protein 1 (AP-1). J. Med. Chem., 2014, 57, 6930-6948.

6)    Ye, N.; Song, Z.; Zhang, A. Dual Ligands Targeting Dopamine D2 and Serotonin 5-HT1A Receptors as New Antipsychotical or Anti-Parkinsonian Agents. Curr. Med. Chem., 2014, 21, 437-457.

7)    Ye, N.; Zhou, J. KRAS - An Evolving Cancer Target. Austin J. Cancer Clin. Res., 2014, 1, 1004.

8)    Ye, N.; Neumeyer, J. L.; Baldessarini, R. J.; Zhen, X.; Zhang, A. Update 1 of: Recent Progress in Development of Dopamine Receptor Subtype-selective Agents: Potential Therapeutics for Neurological and Psychiatric Disorders. Chem. Rev., 2013, 113, PR123-178.

9)    Ye, N.; Chen, C. H.; Chen, T.; Song, Z.; He, J. X.; Huan, X. J.; Song, S. S.; Liu, Q.; Chen, Y.; Ding, J.; Xu, Y.; Miao, Z. H.; Zhang, A. Design, Synthesis, and Biological Evaluation of a Series of Benzo[de][1,7]naphthyridin-7(8H)-ones bearing a Functionalized Longer Chain Appendage as Novel PARP1 Inhibitors. J. Med. Chem., 2013, 56, 2885-2903.

10)  Ye, N.; Xu, X.; Li, F.; Ning, M.; Liu, Z.; Cao, Y.; Leng, Y.; Zhang, A. Investigation on the Oxidation of Aryl Oxiranylmethanols and the Synthesis of 2-Aryl-N-thiazolyl-oxirane-2-carboxamides as Glucokinase Activators. Tetrahedron Lett., 2012, 53, 4738–4742.

11)  Zhang, H.; Ye, N.; # Zhou, S.; Guo, L.; Zheng, L.; Liu, Z.; Gao, B.; Zhen, X.; Zhang, A. Identification of N-Propylnoraporphin-11-yl 5-(1,2-Dithiolan-3-yl)pentanoate as a New Anti-Parkinson’s Agent Possessing a Dopamine D2 and Serotonin 5-HT1A Dual-Agonist Profile. J. Med. Chem., 2011, 54, 4324–4338. (#co-first author)

12)  Ye, N.; Wu, Q.; Zhu, L.; Zheng, L.; Gao, B.; Zhen, X.; Zhang, A. Further SAR Study on 11-O-substituted Aporphine Analogues: Identification of Highly Potent Dopamine D3 Receptor Ligands. Bioorg. Med. Chem., 2011, 19, 1999–2008.

Home | Introduction | Teaching | Faculty and Staff | International Collaborations | Resources | Human Resources | Contact Us
Copyright © 2014 College of Pharmaceutical Sciences, Soochow University · All Rights Reserved